MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

Search

TG Therapeutics Inc

Abierto

SectorSalud

40.88 1.95

Resumen

Variación precio

24h

Actual

Mínimo

39.33

Máximo

41.01

Métricas clave

By Trading Economics

Ingresos

19M

23M

Ventas

24M

108M

P/B

Media del Sector

246.467

57.333

BPA

0.15

Margen de beneficio

21.566

Empleados

338

EBITDA

17M

33M

Recomendaciones

By TipRanks

Recomendaciones

Comprar

Estimación a 12 meses

+6.7% upside

Dividendos

By Dow Jones

Próximas Ganancias

30 abr 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización de Mercado

912M

5.8B

Apertura anterior

38.93

Cierre anterior

40.88

Puntuación técnica

By Trading Central

Confianza

Very Strong Bullish Evidence

TG Therapeutics Inc Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

19 ago 2024, 20:01 UTC

Ganancias

IBD 50 Stock TG Therapeutics Breaks Out Bullishly After 'Solid' Quarter -- IBD

Comparación entre iguales

Cambio de precio

TG Therapeutics Inc Esperado

Precio Objetivo

By TipRanks

6.7% repunte

Estimación a 12 meses

Media 43 USD  6.7%

Máximo 55 USD

Mínimo 11 USD

De acuerdo con 6 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para TG Therapeutics Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

6 ratings

5

Comprar

0

Mantener

1

Vender

Puntuación técnica

By Trading Central

38.41 / 40.35Soporte y Resistencia

Corto Plazo

Very Strong Bullish Evidence

Medio plazo

Neutral Evidence

Largo Plazo

Bullish Evidence

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de TG Therapeutics Inc

TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Umbralisib, an oral inhibitor of PI3K-delta inhibitor for the treatment of adult patients with relapsed or refractory marginal zone lymphoma and follicular lymphoma; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; Rhizen Pharmaceuticals, S A. for the development and commercialization of umbralisib; Jiangsu Hengrui Medicine Co.; and Novimmune SA, as well as collaboration agreement with Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies. TG Therapeutics, Inc. was incorporated in 1993 and is based in Morrisville, North Carolina.